We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Fed. Circ. Won't Revisit Abraxis Loss In Naropin Suit

Law360 (March 14, 2011, 5:26 PM EDT) -- The Federal Circuit denied Abraxis BioScience Inc.'s bid for an en banc rehearing Monday in its battle with generic-drug maker Navinta LLC over three patents for Abraxis' injectable pain management drug...
To view the full article, register now.